Published Dec. 4, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and the first reported death from alpha-gal syndrome. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer and medical director of BioPharma Diagnostics, to explore how biopharma diagnostics advance research and development.

• PAMA reform update (00:33): Get the latest on where reform to PAMA stands following the federal government’s reopening.
• Alpha-gal syndrome case (03:22): Learn about the first known death from alpha-gal syndrome and diagnostic testing for this tick-bite-triggered red meat allergy.
• Biopharma’s role in research and development (07:52): Discover how biopharma diagnostics fuel innovation and how digital tools are expanding its future impact.

Note: Information in this post was accurate at the time of its posting.

Resources

• BioPharma Diagnostics: Connecting pharma and biotech
• Tick-borne disease: An expanding geographic threat

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent news about Protecting Access to Medicare Act (PAMA) reform. Then, Dr. Pritt welcomes Trish Simner, Ph.D., a clinical microbiologist at Mayo Clinic, for an in-depth conversation about metagenomics.

• PAMA reform update and new RESULTS Act (00:30): Hear about options under consideration for PAMA reform, including the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.
• When cerebrospinal fluid (CSF) metagenomics benefit patient care (06:04): Explore how CSF metagenomics work and when it is appropriate to use this advanced diagnostic tool in clinical practice.
• Advancement and innovation in metagenomics (18:15): Discover how recent and upcoming innovation is expanding metagenomic testing capabilities.

Note: Information in this post was accurate at the time of its posting.

Resources

• Answers From the Lab podcast: Developments for LDT Regulation and Laboratory Reimbursement: Bill Morice, M.D., Ph.D.
• Metagenomics: Identifying elusive pathogenic microorganisms

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories. Together, they discuss recent news about virus activity and explore the value of collaboration in shaping innovative diagnostic strategies.

• Testing for viruses appearing closer to home (00:45): Gain insights on using available testing to manage measles and detect chikungunya, which was recently transmitted in the U.S. for the first time in years.
• Collaborating for more coordinated care and innovation (06:04): Explore how strategic partnerships in diagnostics foster innovation and enable a more integrated approach to clinical decision-making.
• Building successful collaborations (12:16): Discover practical insights into establishing and maintaining collaborations that deliver meaningful value to all involved.

Note: Information in this post was accurate at the time of its posting.

Resources

• Answers From the Lab Podcast: How the Evolving Role of Diagnostics and Platforms Impact Healthcare: Bill Morice, M.D., Ph.D.
• Dr. Bill Morice shares how a platform for collaboration transforms diagnostics
• Mary Jo Williamson offers four steps to maximize collaboration benefits

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.

• New podcast format launch (00:25): Drs. Morice and Pritt introduce the exciting new format for “Answers From the Lab,” including the addition of in-depth expert segments.
• Drug-resistant infections (02:05): Discover how clinical diagnostics play a critical role in combating the growing threat of antibiotic resistance.
• Diagnostics’ role in advancing precision medicine (13:28): Learn how diagnostics, specifically drug monitoring, are advancing personalized therapies and contributing to better outcomes.

Note: Information in this post was accurate at the time of its posting.

Resources

• Therapeutics testing: A clear path to accurate answers
• Therapeutics testing at Mayo Clinic Laboratories
• WHO warns of widespread resistance to common antibiotics worldwide
• Tests for infectious disease detection and identification

Connect with Us

• Is there a question or topic you’d like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu.
• Learn more about our hosts and guests and connect with them on social media.
  • Bobbi Pritt, M.D. Bio | LinkedIn
  • Bill Morice, M.D., Ph.D. Bio | LinkedIn
  • Paul Jannetto, Ph.D. Bio | LinkedIn

Published October 16, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent regulatory and policy developments. Together, they explore:

• FDA rescinds rule on LDTs (00:48): The FDA has officially withdrawn its rule that would allow oversight of laboratory-developed tests (LDTs) as medical devices. The conversation explores what this decision means and what might come next for LDT regulation.
• PAMA reform update and new RESULTS Act (05:13): The newly introduced Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act aims to address reimbursement for laboratory tests.
• Getting engaged (12:37): Why it is important to understand new regulatory policies and help others understand their implications for the industry.

Resources

• Find past “Answers From the Lab” podcasts on LDTs and PAMA

Published October 2, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, discuss the latest developments in self-collection testing for women’s health and beyond. Together, they explore:

• New podcast format launching (00:01): Dr. Pritt previews exciting changes coming to “Answers From the Lab.”
• Emerging self-collection tests (01:21): Explore the growing range of self-collection tests now available for use in both clinical settings and at home.
• Validation of self-collection tests (03:19): Learn how laboratorians validated recent self- and home-collection tests to ensure quality and accuracy.
• Benefits for patients and public health (06:56): Understand the benefits self-collection tests offer to patients and how the tests impact public health.
• Limitations and implementation considerations (08:23): Review key factors to consider when incorporating self-collection testing into clinical care.
• Future innovation (11:34): Insights into where self-collection testing may evolve in the years ahead.

Published September 11, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss troublesome organisms making headlines. Together, they explore:

• Vibrio vulnificus (01:09): How people get this “flesh-eating” bacteria, how it affects patients, and a recent case that brought it into the spotlight.
• Staying safe (03:44): Discover when to seek medical attention and how knowledge can protect you as Vibrio vulnificus bacterium becomes more prevalent.
• New World screwworm (06:50): How this parasitic infection damages human tissue, how it was previously eradicated, and why it's making the news again.
• ABCs of protection (12:16): A simple reminder to avoid exposure, use bug spray, and wear protective clothing to shield against hazardous organisms.
• Laboratory as first line of defense (13:34): Laboratorians have a critical role in identification and monitoring broader trends when these types of cases arise.

Resources

• A-Zs for prevention and exposure risks

Cherisse Marcou, Ph.D., and Kristen Rasmussen, M.S., CGC, explain how Mayo Clinic Laboratories' WESPR whole exome sequencing reflex test provides cost-effective diagnosis of complex genetic conditions. Using samples and data from previous targeted gene panels, WESPR's wider net can identify undetected genetic variants.

(00:32)
Would each of you share a little bit about yourselves and your background?

(01:42)

Could you provide us with an overview of the whole exome reflexing panel?

(02:53)
Is this different from our whole exome sequencing panel and our whole exome reanalysis panel?

(04:00)
Tell us more about who benefits from this test.

(06:17)
What is the clinical utility of this testing?

(08:07)

Would you help providers understand how to go about ordering?

(11:23)

Could you tell us more about the types of variants identified by this test?

(13:39)

Based on those performance characteristics, how does our test match up to other exome tests available in the market?

(14:30)

Are there any other unique features you would like to highlight?

(15:57)

What is the turnaround time for the reflex panel?

(16:14)

Can the results from the WESPR test be reanalyzed in the future as new genetic knowledge emerges?

(16:56)

How are variants reported, especially variants of uncertain significance? And does the report include recommendations?

(19:31)

Would you summarize the benefits of the WESPR at Mayo Clinic Laboratories?